| Company Name: |
Jilin Province Woda Biotechnology Co., Ltd.
|
| Tel: |
13504435624 |
| Email: |
1927928688@qq.com |
| Products Intro: |
Product Name:Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 (TFA) CAS:2435572-48-6 Purity:99% HPLC Package:1克;5克;
|
|
| | Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- Basic information |
| Product Name: | Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- | | Synonyms: | Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]-;Thalidomide-O-CONH-C2-O-(C3-O)2-NH2;N-(2-{3-[3-(2-aminoethoxy)propoxy]propoxy}ethyl)-2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}acetamide | | CAS: | 2435572-48-6 | | MF: | C25H34N4O9 | | MW: | 534.56 | | EINECS: | | | Product Categories: | | | Mol File: | 2435572-48-6.mol | ![Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- Structure](CAS/20210305/GIF/2435572-48-6.gif) |
| | Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- Chemical Properties |
| Boiling point | 795.8±60.0 °C(Predicted) | | density | 1.316±0.06 g/cm3(Predicted) | | pka | 10.68±0.40(Predicted) |
| | Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- Usage And Synthesis |
| Uses | Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | | IC 50 | Cereblon | | References | [1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326 [2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1004. DOI:10.1016/S1473-3099(20)30638-1 |
| | Acetamide, N-[2-[3-[3-(2-aminoethoxy)propoxy]propoxy]ethyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]- Preparation Products And Raw materials |
|